Isolation and Characterization of the *Saccharomyces cerevisiae* XPT1 Gene Encoding Xanthine Phosphoribosyl Transferase


Institut de Biochimie et Génétique Cellulaires, CNRS UPR9026, F-33077 Bordeaux Cedex, France, and Department of Biology, Indiana University, Bloomington, Indiana 47405

Received 25 January 1999/Accepted 26 February 1999

A new *Saccharomyces cerevisiae* gene, XPT1, was isolated as a multicopy suppressor of a hypoxanthine phosphoribosyl transferase (HPRT) defect. Disruption of XPT1 affects xanthine utilization in vivo and results in a severe reduction of xanthine phosphoribosyl transferase (XPRT) activity while HPRT is unaffected. We conclude that XPT1 encodes XPRT in yeast.

*Saccharomyces cerevisiae* can use preformed purine bases from the growth medium to synthesize nucleotides. Purine bases are transported into the cell, and the corresponding monophosphate nucleotides are synthesized by phosphoribosyl transferases (Fig. 1). Mutations affecting adenine phosphoribosyl transferase (APRT) and hypoxanthine-guanine phosphoribosyl transferase (HGPRT) in *S. cerevisiae* have been described previously (10, 12, 13). APRT is encoded by the *APT1* gene (2), while *APT2*, a gene encoding a putative PRT highly similar to Apta1p, has been reported (14), although no enzymatic activity could be associated with this protein (1). HGPRT is similar to Apt1p, has been reported (14), although no enzymatic gene (2), while *APT1* was described previously (10, 12, 13). APRT is encoded by the *APT1* gene (2), while *APT2*, a gene encoding a putative PRT highly similar to Apta1p, has been reported (14), although no enzymatic activity could be associated with this protein (1). HGPRT is encoded by the *HPT1* gene (6). An *ade2 hpt1* double mutant is unable to grow on hypoxanthine as a purine source (doubling time, >20 h) but grows on adenine. We took advantage of this phenotype to seek multicopy suppressors of the *ade2 hpt1* double mutant. A multicopy plasmid library (3) was introduced into the *Y916* (MATα ura3-52 leu2-3,112 lys2Δ201 his3Δ200 ade2 hpt1::URA3) strain. About 10⁴ transformants selected on synthetic complete medium (SC) without leucine and with adenine (11) were replica plated to the same medium where adenine and uracil were replaced with hypoxanthine and uracil, respectively. Twenty-four colonies growing on hypoxanthine and uracil were selected, and the corresponding multicopy plasmids were placed into three groups according to similarities in their restriction patterns. The first two groups corresponded to plasmids carrying the *HPT1* or the *ADE2* genes (11 and 8 plasmids, respectively). Three members of the third group were sequenced to determine the boundary of the *XPT1* coding sequence. An EcoRV-BbvI DNA fragment carrying the *xpt1::HIS3* construct was used to transform the yeast strain Y642 (MATα ura3-52 leu2-3,112 lys2Δ201 his3Δ200 trp1::hisG). Transformants were selected for histidine prototrophy. Correct integration was verified by PCR using oligonucleotides from outside the recombination site. No obvious phenotype could be detected as a result of *XPT1* disruption.

Since it has been previously shown that yeast carries a xanthine phosphoribosyl transferase (XPRT) activity that is not affected by *hpt1* mutations (12), we tested whether *XPT1* could encode XPRT. Both hypoxanthine phosphoribosyl transferase (HPRT) and XPRT activities from the wild-type and isogenic *XPT1* disrupted strains were assayed in crude extracts using 8-3H hypoxanthine (Amersham) and 14C xanthine (Sigma) as substrates as described previously (7). HPRT activity was found to be the same in the wild type (5.28 U) and in the *xpt1* strain (6.00 U), while XPRT activity in the *xpt1* disrupted strain was decreased to 6% of wild-type activity (0.043 and 0.760 U, respectively). These values are the means of three independent determinations.

---

**FIG. 1.** Schematic representation of purine interconversion in yeast. Abbreviations: PRPP, 5-phosphoribosyl-1-pyrophosphate; IMP, inosine 5′-monophosphate; XMP, xanthosine 5′-monophosphate; MPA, mycophenolic acid. Genes are indicated in italics and encode the following enzymatic activities: *AAH1*, adenine deaminase; *ADE2*, 5′-phosphoribosyl-5-amino-4-imidazolecarboxylate carboxy-lyase; *APT1*, adenine phosphoribosyl transferase; *HPT1*, hypoxanthine-guanine phosphoribosyl transferase; *XPT1*, xanthine phosphoribosyl transferase. For purposes of simplification, purine nucleosides are not represented.
assays, each assay being done in triplicate. For each value, the standard deviation was <12%.

This result prompted us to evaluate whether disruption of the \(XPT1\) gene would affect xanthine utilization in vivo. This was done by blocking XMP synthesis with mycophenolic acid (MPA) (100 mg/liter). Under these conditions, yeast cells cannot synthesize GMP so they stop growing. This phenotype can be rescued by extracellular guanine, which can be transformed to GMP by HGPRT, the product of the \(HPT1\) gene (12). The effect of MPA can also be bypassed by extracellular xanthine if this base is transformed to XMP by XPRT. We have tested the growth capacity of \(hpt1\) and \(xpt1\) isogenic mutant strains in the presence of MPA supplemented with guanine or xanthine. Growth of the wild-type strain (Fig. 2A) was inhibited by MPA, and this inhibition was rescued totally by guanine and partially by xanthine, suggesting that the latter was not very efficiently transported or transformed to XMP. In the \(xpt1\) mutant strain, inhibition by MPA was totally rescued by guanine but not at all by xanthine (Fig. 2B). Therefore, \(XPT1\) appears necessary for xanthine utilization but does not significantly affect guanine utilization. In the \(hpt1\) mutant (Fig. 2C), guanine could only partially rescue MPA inhibition, confirming that \(HPT1\) encodes most of the HGPRT activity. In this mutant, xanthine was able to rescue MPA inhibition just as in the wild-type strain. This result is in good agreement with the fact that XPRT activity is unaffected in the \(hpt1\) mutant (12). Finally, in the \(hpt1\ xpt1\) double mutant (Fig. 2D), neither guanine nor xanthine affected growth in the presence of MPA. We conclude from these experiments that \(XPT1\) is required for xanthine utilization in yeast and for optimal utilization of guanine, at least in an \(hpt1\) mutant strain (compare Fig. 2C and D).

This study completes the identification of purine phospho-

FIG. 2. Effect of mutations in the \(HPT1\) and \(XPT1\) genes on guanine and xanthine utilization. Growth was monitored by recording the optical density at 600 nm (OD600) as a function of time on SC (black dots), SC plus MPA (open circles), SC plus MPA plus guanine (squares), and SC plus MPA plus xanthine (triangles). Growth of the following strains was assayed: Y642 (\(HPT1\ XPT1\)) (A), Y652 (\(HPT1\ xpt1\)) (B), Y670 (\(hpt1\ XPT1\)) (C), and Y700 (\(hpt1\ xpt1\)) (D).
ribozyme transferases in *S. cerevisiae*. In this organism, it therefore appears that three genes are responsible for synthesizing monophosphate nucleotides from the corresponding purine bases. *HPT1* and *APT1* encode HPRT and APRT, respectively (2, 6). In this study, we identify the *XPT1* gene encoding XPRT. It is noteworthy that an aspartic acid residue that has been shown to be critical for xanthine recognition by *Tritrichomona foetus* HGPRT (9) is found in Xpt1p at position 192 but not in Hpt1p, where a glutamic acid is found at the equivalent position (position 194 in HPRT). Finally, our data suggest that Xpt1p can also utilize hypoxanthine as a substrate, since overexpression of *XPT1* can partially alleviate the growth defect of a mutant lacking HGPRT. Nevertheless, utilization of hypoxanthine by Xpt1p does not allow full complementation of the *ade2 hpt1* growth defect.

We thank V. Denis for his critical reading of the manuscript. This work was supported by grants from Association pour la Recherche sur le Cancer (4032), Fondation pour la Recherche Médicale, Conseil Régional d’Aquitaine and CNRS (UPR9026). M.L.G. was supported by a Ministère des Affaires Etrangères fellowship.

REFERENCES